PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Tumor-specific targeting with fluorescent probes can enhance contrast for identification cancer during surgical resection and visualize otherwise invisible tumor margins. Fluorescent probes derived from nanobodies, the smallest naturally occurring antigen binding molecules, can be used for in-vivo labeling with rapid pharmacokinetics. The present work demonstrates the efficacy of a fluorescent anti-CEA nanobody conjugated to an IR800 dye to target and label patient derived pancreatic cancer xenografts. After intravenous administration, the probe clearly localized to the pancreatic cancer tumors and had a tumor-to-background ratio of 2 or greater by 1 hour. Tumor-specific fluorescent nanobodies are clinically promising molecules for same-day labeling and imaging of tumors.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Thinzar M. Lwin M.D., Michael A. Turner M.D., Nishino Hiroto M.D., Sophie Hernot, Michael Bouvet M.D., "Fluorescent anti-CEA nanobody for rapid tumor-specific fluorescence labeling of patient-derived pancreatic cancer xenografts," Proc. SPIE PC11943, Molecular-Guided Surgery: Molecules, Devices, and Applications VIII, PC1194307 (7 March 2022); https://doi.org/10.1117/12.2609973